View Item 

Show simple item record

Renal function with cyclosporine C 2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients
dc.contributor.authorCibrik, Diane M.en_US
dc.contributor.authorMeier-Kriesche, Herwig-Ulfen_US
dc.contributor.authorBresnahan, Barbaraen_US
dc.contributor.authorWu, You Minen_US
dc.contributor.authorKlintmalm, Goran B.en_US
dc.contributor.authorKew, Clifton E.en_US
dc.contributor.authorKuo, Paul C.en_US
dc.contributor.authorWhelchel, Johnen_US
dc.contributor.authorCohen, Daviden_US
dc.contributor.authorBaliga, Prabakaren_US
dc.contributor.authorAkalin, Enveren_US
dc.contributor.authorBenedetti, Enricoen_US
dc.contributor.authorWright, Francisen_US
dc.contributor.authorLieberman, Bonnieen_US
dc.contributor.authorUlbricht, Bettinaen_US
dc.contributor.authorJensik, Stephenen_US
dc.date.accessioned2010-06-01T18:44:34Z
dc.date.available2010-06-01T18:44:34Z
dc.date.issued2007-03en_US
dc.identifier.citationCibrik, Diane; Meier-Kriesche, Herwig-Ulf; Bresnahan, Barbara; Wu, You Min; Klintmalm, Goran; Kew, Clifton E.; Kuo, Paul C; Whelchel, John; Cohen, David; Baliga, Prabakar; Akalin, Enver; Benedetti, Enrico; Wright, Francis; Lieberman, Bonnie; Ulbricht, Bettina; Jensik, Stephen (2007). "Renal function with cyclosporine C 2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients." Clinical Transplantation 21(2): 192-201. <http://hdl.handle.net/2027.42/71940>en_US
dc.identifier.issn0902-0063en_US
dc.identifier.issn1399-0012en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/71940
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17425744&dopt=citationen_US
dc.format.extent576836 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights2007 Blackwell Munksgaarden_US
dc.subject.otherC 2 Monitoringen_US
dc.subject.otherCyclosporine Microemulsionen_US
dc.subject.otherEnteric-coated Mycophenolate Sodiumen_US
dc.subject.otherHigh-risk Recipienten_US
dc.subject.otherKidney Transplanten_US
dc.subject.otherMyforticen_US
dc.subject.otherRenal Functionen_US
dc.titleRenal function with cyclosporine C 2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipientsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationotherDepartment of Medicine, University of Florida, Gainesville, FLen_US
dc.contributor.affiliationotherDepartment of Nephrology, Medical College of Wisconsin, Milwaukee, WIen_US
dc.contributor.affiliationotherTransplant Services, University of Arkansas Medical School, Little Rock, ARen_US
dc.contributor.affiliationotherTransplantation Services, Baylor University Medical Center, Dallas, TXen_US
dc.contributor.affiliationotherDepartment of Nephrology, University of Alabama, Birmingham, ALen_US
dc.contributor.affiliationotherDepartment of Surgery, Duke University Medical Center, Durham, NCen_US
dc.contributor.affiliationotherTransplantation Services, Piedmont Hospital, Atlanta, GAen_US
dc.contributor.affiliationotherDepartment of Medicine, Columbia University Medical Center, New York, NYen_US
dc.contributor.affiliationotherMedical University of South Carolina, Charleston, SCen_US
dc.contributor.affiliationotherMount Sinai Medical Center, Recanati/Miller Transplant Institute, New York, NYen_US
dc.contributor.affiliationotherUniversity of Illinois at Chicago, Chicago, ILen_US
dc.contributor.affiliationotherMethodist Specialty and Transplant Hospital, San Antonio, TXen_US
dc.contributor.affiliationotherMedical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, NJen_US
dc.contributor.affiliationotherOrgan and Tissue Transplant Services, Rush-Presbyterian, St. Luke's Medical Center, Chicago, IL, USAen_US
dc.identifier.pmid17425744en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/71940/1/j.1399-0012.2006.00622.x.pdf
dc.identifier.doi10.1111/j.1399-0012.2006.00622.xen_US
dc.identifier.sourceClinical Transplantationen_US
dc.identifier.citedreferenceMeier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004: 4: 378.en_US
dc.identifier.citedreferenceCecka & Terasaki ( eds ). Clinical Transplants. UCLA Immunogenetics Center, Los Angeles, CA, 1999.en_US
dc.identifier.citedreferenceKreis H, Cisterne JM, Land W et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000: 69: 1252.en_US
dc.identifier.citedreferenceGroth CG, Backman L, Morales JM. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999: 67: 1036.en_US
dc.identifier.citedreferenceJohnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001: 72: 777.en_US
dc.identifier.citedreferenceVincenti F, Ramos E, Brattstrom C et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001: 71: 1282.en_US
dc.identifier.citedreferenceThervet E, Pfeffer P, Scolari MP et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C 2 monitoring of cyclosporin microemulsion. Transplantation 2003: 76: 903.en_US
dc.identifier.citedreferenceLevy G, Burra P, Cavallari A et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C 2 ). Transplantation 2002: 73: 953.en_US
dc.identifier.citedreferenceCantarovich M, Barkun JS, Tchervenkov JI, Besner JF, Aspeslet L, Metrakos P. Comparison of Neoral dose monitoring with cyclosporine trough levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation 1998: 66: 1621.en_US
dc.identifier.citedreferenceCantarovich M, Besner J-G, Barkun JS, Elstein E, Loertscher R. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 1998: 12: 243.en_US
dc.identifier.citedreferenceMahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the curve is the appropriate tool to monitor Neoral therapy. Transplantation 1999: 68: 55.en_US
dc.identifier.citedreferenceKelles A, Herman J, Tjandra-Maga TB, Van Damme-Lombaerts R. Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients. Pediatr Transplant 1999: 3: 282.en_US
dc.identifier.citedreferenceGrant D, Kneteman N, Tchervenkov J et al. Peak cyclosporine levels (C max ) correlate with freedom from liver graft rejection. Transplantation 1999: 67: 1133.en_US
dc.identifier.citedreferenceLevy G, Thervet E, Lake J, Uchida K. Consensus on Neoral C(2): Expert Review in Transplantation (CONCERT) Group. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation 2002: 73 ( Suppl. ): S12.en_US
dc.identifier.citedreferenceNashan B, Bock A, Bosmans J-L et al. Use of Neoral C 2 monitoring: a European consensus. Transpl Int 2005: 18: 768.en_US
dc.identifier.citedreferenceSollinger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995: 60: 225.en_US
dc.identifier.citedreference17. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized, clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996: 61: 1029.en_US
dc.identifier.citedreferenceOjo AO, Meier-Kriesche HU, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000: 69: 2405.en_US
dc.identifier.citedreferenceSalvadori M, Holzer H, de Mattos A et al. on behalf of the ERL B301 Study Groups. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004: 4: 231.en_US
dc.identifier.citedreferenceBudde K, Curtis J, Knoll G et al. on behalf of the ERL B302 Study Group. Enteric-coated mycophenolate sodium can be safety administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004: 4: 237.en_US
dc.identifier.citedreferenceRacusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713.en_US
dc.identifier.citedreferenceCockcroft RW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976: 16: 31.en_US
dc.identifier.citedreferenceStefoni A, Midtvedt K, Cole E et al. MO2ART Study Group. Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine A microemulsion: results of a 12-month, randomized, multicenter study. Transplantation 2005: 79: 577.en_US
dc.identifier.citedreference24. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation 2001: 72: 1024.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1399-0012.2006.00622.x.pdf
Size:
563.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.